[Defects in the prostaglandin system. VIII. A pathologic thrombocyte population in myeloproliferative syndrome, which forms no thromboxane from exogenous arachidonic acid].
In 2 out of 29 patients suffering from the myeloproliferative syndrome a lack of thromboxane conversion by platelets from exogenous arachidonic acid was discovered. In one patient PGE2 (30.9%) and 12-HETE (12-Hydroxyeicosatetraenoic acid) (42.8%) were formed instead, whilst in the other patient 12-HETE (72.9%) was the main metabolic product. In both the patients, serum and plasma TXB2, as well as malondialdehyde, were quite low. It is claimed that this phenomenon is due to the expression of a pathological population of platelets related to the disease.
Sinzinger
H
H
II. Medizinische Universitätsklinik, Wien.
Gisslinger
H
H
Linkesch
W
W
Ludwig
H
H
Flener
R
R
Peskar
B A
BA
D000368:Aged; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood*; D001792:Blood Platelets / Q000378:metabolism*; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009196:Myeloproliferative Disorders / Q000097:blood*; D010979:Platelet Function Tests; D011087:Polycythemia Vera / Q000097:blood; D013922:Thrombocytosis / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood*
D001095:Arachidonic Acids; D016718:Arachidonic Acid; D008315:Malondialdehyde; D013929:Thromboxane B2
Defekte im Prostaglandinsystem. VIII. Eine pathologische Thrombozytenpopulation bei myeloproliferativem Syndrom, die aus exogener Arachidonsäure kein Thromboxan bildet.